AI-Generated Filing Summaries

Exact Sciences Corporation completed its merger with Badger Merger Sub I, Inc., becoming a direct wholly owned subsidiary of Abbott Laboratories on March 23, 2026, with shareholders receiving $105.00 per share in cash totaling approximately $21 billion. The company terminated its credit agreement, modified convertible notes conversion rights to cash, delisted from Nasdaq, and saw all directors and officers depart.

Azitra, Inc. entered a Securities Purchase Agreement on March 18, 2026, issuing 10,485 shares of Series A convertible non-redeemable preferred stock at $1,000 each, plus Series B and C warrants to purchase up to 85,233,126 shares of common stock each at $0.123 exercise price, in a PIPE Financing closing March 20, 2026, for initial $10.5 million proceeds, potentially $31.4 million total. Funds support R&D, corporate expenses, and working capital.

MAIA Biotechnology, Inc. (MAIA), a clinical-stage biopharmaceutical company, reported a net loss of $22.4 million for FY 2025 ended December 31, 2025, an improvement from $23.3 million in FY 2024, driven by a $1.9 million other income net versus prior expense, offsetting higher operating costs. Total operating expenses rose 43% YoY to $24.3 million, with R&D up 45% to $14.5 million due to increased clinical trial activities for lead asset ateganosine (THIO-101 expansion and THIO-104 Phase 3 initiation) and preclinical research, and G&A up 40% to $9.7 million from investor relations and personnel costs. No revenue was generated, consistent with pre-commercial stage. Balance sheet shows $9.7 million total assets, including $8.7 million cash, $2.4 million equity, and $7.3 million liabilities. Cash used in operations was $18.8 million, funded by $17.9 million financing (ATM offerings $7.2 million net, private placements). Ending cash $8.7 million supports ongoing trials, but additional capital needed for Phase 3 and commercialization. Forward-looking, FDA Fast Track for ateganosine in NSCLC, NIH $2.3M grant, and partnerships (Regeneron, BeOne, Roche) signal progress toward 2026 accelerated approval filing.

Energy Services of America Corporation updated its investor relations slide deck on March 23, 2026, for 1x1 investor presentations at the 38 th Annual ROTH Conference in Data Point, California. The slide deck is available on the Company’s website at www.energyservicesofamerica.com.

The Crypto Company entered into a Mutual Transfer and Release Agreement dated March 19, 2026, effective October 16, 2025, rescinding ab initio the October 8, 2025 Securities Purchase Agreement under which it acquired 50.1% of Starchive.io, Inc. The Company returned the Starchive shares to sellers, received cancellation of 433,633,691 common shares and all convertible notes, and issued 151,748,756 new common shares to Starchive as restricted securities exempt under Section 4(a)(2).

MIRA Pharmaceuticals reported preclinical data showing Mira-55 produced no THC- or rimonabant-associated CNS side effects, including no psychogenic effects, sedation, catalepsy, motor impairment, or anxiogenic effects at oral doses of 10, 30, and 100 mg/kg. These results build on prior morphine-comparable pain relief in inflammatory pain models without opioid risks, supporting planned IND submission for inflammatory pain.

Ondas Inc. reported record Q4 2025 revenue of $30.1 million and full-year 2025 revenue of $50.7 million, meeting the high end of pre-announced targets and representing 605% year-over-year growth. The company raised its full-year 2026 revenue target to at least $375 million and Q1 2026 target to $38-$40 million, with $594.4 million in cash, cash equivalents and restricted cash as of December 31, 2025.

GMEX Robotics Corporation announced a AU$4.2 million purchase agreement with a leading Australian food and beverage group for deployment of intelligent culinary robotics systems, including a minimum of 50 Smart Digital Intelligence All-in-One Kitchen Robots such as Bon Vivant 3.0 and Max models. This marks the company's first commercial agreement with a restaurant group since launching its cooking robotics platform in December 2025 and rebranding from Fitell Corporation.

Crinetics Pharmaceuticals, Inc. disclosed that Jeff Knight resigned as Chief Development and Operating Officer, effective on or about April 10, 2026, after notifying the company on March 17, 2026. The resignation is to pursue another opportunity with no disagreement on operations, policies, or practices, and his responsibilities will be reassigned to the executive leadership team.

Frontier Nuclear and Minerals Inc. provided a corporate update advancing its U.S. nuclear fuel cycle strategy, including uranium assets at Tallahassee Project (Colorado) and Pine Ridge Project (Wyoming), equity in Ubaryon and Kadmos Energy, and planned spin-off of non-core lithium assets to simplify operations and enhance focus.

ASP Isotopes Inc. completed the drilling of wells required for Phase 1 of the Renergen Helium Project four months ahead of schedule, achieving cumulative nameplate flow rates that meet or exceed type curves and reduce execution risk. This milestone supports ramp-up to helium plant capacity amid Qatar helium supply disruptions.

Scinai Immunotherapeutics Ltd. executed a Second Amendment to its Binding Option Agreement for the acquisition of PinCell S.r.l., extending the option conditions deadline to August 31, 2026, and option exercise period to September 30, 2026, and submitted a revised €12 million non-dilutive FENG SMART Path application for an integrated €15 million R&D program for PC111. The funding, if awarded, would support advancement through human proof of concept while preserving balance sheet flexibility.

TTEC Holdings, Inc. announced the departure of David J. Seybold as Chief Executive Officer of TTEC Digital effective April 30, 2026, to pursue other opportunities, and the immediate appointment of Christopher J. Brown as President of TTEC Digital. Brown will enter an employment agreement with base salary of $500,000, variable incentive up to $450,000, and long-term incentive up to $425,000.

Envoy Medical, Inc. (COCH) reported net revenues of $241K for FY 2025, up 7.1% YoY from $225K in FY 2024, driven by nominal sales of Esteem FI-AMEI implants and components. However, the company posted an operating loss of $22.3M, widening 15.7% YoY from $19.3M, due to elevated R&D expenses of $12.5M (up 22.7%) from Acclaim CI clinical trials, including full enrollment of 56 patients. Total operating expenses rose 15.6% to $22.5M, with G&A up 16.2% amid severance and consulting costs. Net loss expanded to $23.8M (14.2% YoY worse) from $20.8M, reflecting $1.5M other expenses including related-party interest. Net loss per share remained at -$1 on 23.3M weighted shares. Balance sheet shows $8.6M total assets, $3.7M cash, but $20.3M liabilities exceed $12.2M stockholders' deficit. Cash used in operations was $18.2M, offset by $16.6M financing inflows from $10.0M related-party Term Loans and $6.5M offerings. Forward-looking, FDA PMA submission targeted post-12-month trial data, eyeing approval in late 2027/early 2028, with liquidity into Q2 2027 barring warrant exercises.

Envoy Medical, Inc. (COCH) reported net revenues of $241K for FY 2025, up 7.1% YoY from $225K in FY 2024, driven by nominal sales of Esteem FI-AMEI implants and components. However, the company posted an operating loss of $22.3M, widening 15.7% YoY from $19.3M, due to elevated R&D expenses of $12.5M (up 22.7%) from Acclaim CI clinical trials, including full enrollment of 56 patients. Total operating expenses rose 15.6% to $22.5M, with G&A up 16.2% amid severance and consulting costs. Net loss expanded to $23.8M (14.2% YoY worse) from $20.8M, reflecting $1.5M other expenses including related-party interest. Net loss per share remained at -$1 on 23.3M weighted shares. Balance sheet shows $8.6M total assets, $3.7M cash, but $20.3M liabilities exceed $12.2M stockholders' deficit. Cash used in operations was $18.2M, offset by $16.6M financing inflows from $10.0M related-party Term Loans and $6.5M offerings. Forward-looking, FDA PMA submission targeted post-12-month trial data, eyeing approval in late 2027/early 2028, with liquidity into Q2 2027 barring warrant exercises.

Ondas Holdings Inc. entered into a definitive Agreement and Plan of Merger dated March 23, 2026, to acquire World View Enterprises Inc. for $150 million primarily in common stock (up to ~$129.5 million), enhancing its multi-domain ISR platform with stratospheric sensing capabilities. The deal builds on a prior $10 million investment and is expected to close in Q2 2026.

On March 23, 2026, Strategy Inc entered joinders adding Moelis & Company LLC, A.G.P./Alliance Global Partners, and StoneX Financial Inc. as sales agents under the Omnibus Sales Agreement dated November 4, 2025, and additional program addendums for ATM offerings of up to $21.0 billion Common Stock, $21.0 billion STRC Preferred Stock, and $2.1 billion STRK Preferred Stock. The company filed certificates increasing authorized STRC Preferred shares to 282,556,565 and decreasing STRK Preferred shares to 40,270,744, terminating the prior STRK offering effective March 22, 2026.

On March 23, 2026, Strategy Inc entered joinders adding Moelis & Company LLC, A.G.P./Alliance Global Partners, and StoneX Financial Inc. as sales agents under the Omnibus Sales Agreement dated November 4, 2025, and additional program addendums for ATM offerings of up to $21.0 billion Common Stock, $21.0 billion STRC Preferred Stock, and $2.1 billion STRK Preferred Stock. The company filed certificates increasing authorized STRC Preferred shares to 282,556,565 and decreasing STRK Preferred shares to 40,270,744, terminating the prior STRK offering effective March 22, 2026.

On March 23, 2026, Strategy Inc entered joinders adding Moelis & Company LLC, A.G.P./Alliance Global Partners, and StoneX Financial Inc. as sales agents under the Omnibus Sales Agreement dated November 4, 2025, and additional program addendums for ATM offerings of up to $21.0 billion Common Stock, $21.0 billion STRC Preferred Stock, and $2.1 billion STRK Preferred Stock. The company filed certificates increasing authorized STRC Preferred shares to 282,556,565 and decreasing STRK Preferred shares to 40,270,744, terminating the prior STRK offering effective March 22, 2026.

On March 23, 2026, Strategy Inc entered joinders adding Moelis & Company LLC, A.G.P./Alliance Global Partners, and StoneX Financial Inc. as sales agents under the Omnibus Sales Agreement dated November 4, 2025, and additional program addendums for ATM offerings of up to $21.0 billion Common Stock, $21.0 billion STRC Preferred Stock, and $2.1 billion STRK Preferred Stock. The company filed certificates increasing authorized STRC Preferred shares to 282,556,565 and decreasing STRK Preferred shares to 40,270,744, terminating the prior STRK offering effective March 22, 2026.

On March 23, 2026, Strategy Inc entered joinders adding Moelis & Company LLC, A.G.P./Alliance Global Partners, and StoneX Financial Inc. as sales agents under the Omnibus Sales Agreement dated November 4, 2025, and additional program addendums for ATM offerings of up to $21.0 billion Common Stock, $21.0 billion STRC Preferred Stock, and $2.1 billion STRK Preferred Stock. The company filed certificates increasing authorized STRC Preferred shares to 282,556,565 and decreasing STRK Preferred shares to 40,270,744, terminating the prior STRK offering effective March 22, 2026.

Off The Hook YS Inc. announced the launch of NextBoat AI, an industry-first AI matching platform designed to help consumers identify and acquire their ideal next boat faster using proprietary market data and AI. The platform, refined over two years, will debut at the Palm Beach International Boat Show from March 25–29, 2026, enhancing marketplace efficiency.

SunPower furnished its presentation at the 38th Annual ROTH Conference as Exhibit 99.1 under Item 7.01 on March 23, 2026, disclosing preliminary Q4'25 revenue of $88.5 million, four consecutive quarters of operating income profit, acquisitions of Sunder ($90M revenue), Ambia ($80M), and contemplated Cobalt ($30M), funded by $150M convertible debentures, with plans for $1B revenue in 2028.

Otter Tail Power Company, a subsidiary of Otter Tail Corporation, entered into a Note Purchase Agreement on March 19, 2026, to issue $170 million aggregate principal of senior unsecured notes: $100 million 5.33% Series 2026A due 2036 (issued March 19, 2026) and $70 million 6.04% Series 2026B due 2056 (expected June 4, 2026). Proceeds will fund capital expenditures, refinance existing indebtedness, and general corporate purposes.

Chunghwa Telecom Co., Ltd. disclosed that on March 20, 2026, the Daan Precinct of Taipei City Police Department raided the staff offices of its local business operation centers. The company is fully cooperating with the investigation, with no effect on its finances or business.

Dr. Reddy's Laboratories Limited informed that a Board of Directors meeting will be held on May 12, 2026, to consider the Audited Standalone and Consolidated Financial Results for the quarter and financial year ending March 31, 2026. The trading window for dealing in the company's securities will be closed from March 25, 2026, to May 14, 2026 (both days inclusive).

Genmab A/S filed Exhibit 3.1, an English translation of its Articles of Association dated March 19, 2026, confirming share capital of DKK 64,250,721 and Board of Directors authorizations for capital increases up to DKK 6,600,000 without or with pre-emption rights until March 12, 2029, employee warrants under three programs up to DKK 750,000 each, and convertible debt instruments up to DKK 3,000,000 new shares.

Genmab A/S filed Exhibit 3.1, an English translation of its Articles of Association dated March 19, 2026, confirming share capital of DKK 64,250,721 and Board of Directors authorizations for capital increases up to DKK 6,600,000 without or with pre-emption rights until March 12, 2029, employee warrants under three programs up to DKK 750,000 each, and convertible debt instruments up to DKK 3,000,000 new shares.

Organigram Global Inc. announced that ISS recommends shareholders vote FOR the Transaction Resolution approving the indirect acquisition of Sanity Group GmbH at the March 30, 2026 shareholder meeting, highlighting compelling strategic rationale, BAT's premium financing signaling institutional confidence, credible valuation, and positive market reaction. This endorsement underscores strong support for the €113.4 million upfront deal with potential €113.8 million earn-out.

The 10-K filing for BBCMS Mortgage Trust 2021-C9, dated March 23, 2026, covers the fiscal year ended December 31, 2025. As a commercial mortgage-backed securities (CMBS) trust, no traditional financial statements or XBRL data are provided; Item 8 is omitted. The report emphasizes compliance with Regulation AB servicing criteria under Items 1122 and 1123. Management and servicers, including Midland Loan Services (master servicer), K-Star Asset Management (special servicer), KeyBank National Association (primary servicer for key loans), and others like Wells Fargo and Computershare, assert material compliance for their roles. Key loans highlighted: The Atlantic Mortgage Loan (9.4% of pool), MGM Grand & Mandalay Bay (7.3%), Crescent Gateway (4.0%), Seaport Homes (1.8%), McCarthy Ranch (0.6%). No delinquencies, losses, or material legal proceedings noted (Item 1117). Servicing transfers and vendor roles detailed, with attestations from auditors like PwC and KPMG confirming compliance. No significant changes in performance metrics; focus remains on operational adherence amid pari passu loan structures across related deals. Investor relevance: Confirms ongoing servicing integrity for pool assets totaling undisclosed principal, with no single obligor exceeding 10%.